Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zhuhai Beston Technology

Request full access

A company developing cell therapy and gene therapy products

ChinaFounded 2021Biotech & Life Sciences

About Zhuhai Beston Technology

Operating at the forefront of genetic medicine, Base Therapeutics is a clinical-stage biopharmaceutical company established in 2021. The company was co-founded by former Baylor medical school classmates Dr. Huang Xingxu and Dr. Xu Tianhong, who now serves as CEO. The founding team merges scientific acumen with industry leadership, including highly cited scientists in the gene-editing field and seasoned entrepreneurs.

The firm is centered on developing therapies for cancer and genetic diseases through next-generation gene editing technologies, specifically base editing and prime editing. Base editing is a precise method of altering a single nucleotide in the DNA sequence without making a double-stranded break, which reduces the risk of unintended mutations compared to traditional CRISPR-Cas9 methods. The company's core technology is its proprietary AccuBase® base editing system, a protein-based platform that enables highly efficient gene editing with what the company describes as zero off-target effects. This system, for which Base Therapeutics has global freedom to operate (FTO) and multiple patents, is designed for both in-vitro and in-vivo applications.

Base Therapeutics' business model involves both internal pipeline development and strategic collaborations. The company generates revenue by licensing its AccuBase® technology to other pharmaceutical companies for use in their respective fields, including CAR-T therapies. Its internal pipeline is focused on developing off-the-shelf, universal cell therapies. A lead candidate is NK510, a base-edited Natural Killer (NK) cell product designed to treat solid tumors. In late 2024, NK510 received Investigational New Drug (IND) approvals from both the U.S. FDA and China's NMPA, a significant milestone marking the first base-edited NK cell therapy to enter clinical trials. The company also has other products in development, including treatments for hematological malignancies and autoimmune diseases, and explores applications in agriculture.

Headquartered in Shanghai, the company has established a substantial infrastructure, including a 2,500-square-meter GMP-compliant manufacturing facility to support clinical trials and production. With backing from top-tier biopharma investors like Gobi Partners and Baidu Ventures, Base Therapeutics has secured significant funding through Seed and Series A rounds to advance its research, clinical trials, and international expansion, with a focus on the Greater Bay Area via its Hong Kong office.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2024 $2.8M $100M Gobi Ventures ↗
SERIES A✓Equity / VC Jan 2023 $20M $80M Honghui Capital · Broad Huitong · Spark Ventures · Baidu Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Zhuhai Beston Technology website traffic

Latest recorded traffic for Zhuhai Beston Technology is 960 monthly website visits, up 357.1% over the last three months.

Latest monthly visits960 3-month web change+357.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zhuhai Beston Technology in its local ecosystem

Live from Dealroom

The Zhuhai Beston Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Honghui Capital
  • Broad Huitong
  • Spark Ventures
  • Baidu Ventures
  • Xinxi Capital
  • Great Eagle VC
  • Gobi Ventures

Other known investors1 additional known investor

  • Gobi Partners
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zhuhai Beston Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zhuhai Beston Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.